NEO'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
Neogenomics Inc NEO'ün son çeyrekteki geliri nasıl performans gösterdi?
Neogenomics Inc'in gelir tahmini nedir?
Neogenomics Inc'in kazanç kalite puanı nedir?
Neogenomics Inc kazançlarını ne zaman rapor eder?
Neogenomics Inc'in beklenen kazançları nelerdir?
Neogenomics Inc kazanç beklentilerini aştı mı?
Önemli İstatistikler
Önceki Kapanış
$11.5
Açılış fiyatı
$11.53
Günün Aralığı
$11.11 - $11.56
52 haftalık aralık
$4.72 - $14.73
İşlem hacmi
855.1K
Ort.Hacim
1.8M
EPS (TTM)
-0.89
Dividend yield
--
Piyasa Değeri
$1.4B
NEO nedir?
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,200 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.